VA
TRVI icon

VR Adviser’s Trevi Therapeutics TRVI Stock Holding History

VR Adviser’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-615,506
Closed -$3.87M – 40
2025
Q1 		$3.87M Sell
615,506
-650,951
-51% -$3.11M 0.33% 28
2024
Q4 		$5.22M Sell
1,266,457
-2,156,199
-63% -$6.9M 0.36% 30
2024
Q3 		$11.4M Buy
3,422,656
+19
+0% +$56 0.6% 28
2024
Q2 		$10.2M Sell
3,422,637
-38
-0% -$106 0.65% 30
2024
Q1 		$11.8M Buy
3,422,675
+278
+0% +$620 0.56% 33
2023
Q4 		$4.59M Hold
3,422,397
– – 0.31% 33
2023
Q3 		$7.46M Hold
3,422,397
– – 0.79% 28
2023
Q2 		$8.18M Buy
3,422,397
+372,375
+12% +$938K 1.31% 18
2023
Q1 		$5.64M Hold
3,050,022
– – 1.1% 20
2022
Q4 		$5.89M Hold
3,050,022
– – 0.99% 22
2022
Q3 		$4.7M Hold
3,050,022
– – 0.72% 25
2022
Q2 		$8.57M Buy
+3,050,022
New +$7.49M 1.69% 17

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

VR Adviser's TRVI Position: Q2 2025 in Review

VR Adviser sold out of Trevi Therapeutics (TRVI) in Q2 2025, closing a stake of 615,506 shares — an estimated $3.87M sold.

VR Adviser first reported a position in TRVI in Q2 2022 and held it in 12 quarters. The position peaked at $11.8M in Q1 2024. 153 funds tracked by Wall St. Rank hold TRVI as of Q2 2025.

  • VR Adviser reported no remaining Trevi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • VR Adviser sold 615,506 Trevi Therapeutics shares in Q2 2025, an estimated $3.87M.
  • VR Adviser first reported a position in Trevi Therapeutics in Q2 2022 and held it in 12 quarters.
  • VR Adviser's Trevi Therapeutics position peaked at $11.8M in Q1 2024.
  • 153 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2025.

Based on VR Adviser's 13F filing for Q2 2025, filed 14 Aug 2025.